NCT05268939View on ClinicalTrials.gov

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

NACompletedINTERVENTIONAL
Enrollment

668

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

April 25, 2022

Study Completion Date

March 14, 2023

Conditions
COVID-19Influenza AInfluenza Type BRSV Infection
Interventions
DIAGNOSTIC_TEST

LumiraDx SARS-CoV-2 & Flu A/B test

Swab Samples for Diagnostic test

DIAGNOSTIC_TEST

LumiraDx SARS-CoV-2 & RSV test

Swab Samples for Diagnostic test

Trial Locations (8)

33155

Marisela Gonzalez, MD, PA, Miami

33169

Excellence Medical and Research, Miami Gardens

35055

Cullman Clinical Trials, Cullman

44130

Clinical Research Solutions, Middleburg Heights

61550

Koch Family Medicine, Morton

70433

Benchmark Research, Covington

89104

Machuca Foundation, Las Vegas

92024

Diagnamics, Inc, Encinitas

All Listed Sponsors
lead

LumiraDx UK Limited

INDUSTRY

NCT05268939 - Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19 | Biotech Hunter | Biotech Hunter